Adriane Fugh-Berman, MD
Potential Financial Conflicts of Interest: Dr. Fugh-Berman has been a paid expert witness on the plaintiff's side in litigation regarding pharmaceutical marketing practices. She directs PharmedOut.org, a project funded through the Attorney General Consumer and Prescriber Grant Program.
Fugh-Berman A.; Prescriber Profiling. Ann Intern Med. 2008;148:82. doi: 10.7326/0003-4819-148-1-200801010-00015
Download citation file:
Published: Ann Intern Med. 2008;148(1):82.
TO THE EDITOR:
Grande notes that participation in the AMA's PDRP has been low (1). Widespread participation, however, would constitute only a minor impediment to prescription tracking. The PDRP restricts only drug representatives and their immediate supervisors from accessing brand-specific prescribing information for individual physicians (2). Any pharmaceutical company employees above that level have full access to details of physicians' prescribing habits. The restrictions also do not apply to “deciles at the market or therapeutic class level” (2), which means that drug representatives still have access to specific information, for example, that Dr. X prescribes more antidepressants than 90% of his peers and more antipsychotics than 70% of his peers. Also, when a physician signs up for the PDRP, what few restrictions apply may not go into effect for 3 months, and the restrictions expire 3 years after sign-up (3).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only